Biogen Overview
Biogen (BIIB) has a P/E ratio of 38.17, above the Healthcare sector average of 26.85.
Get informed when a big investor buys or sells
+ Follow38.17
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
As of the most recent data, BIIB shows a P/E ratio of 38.17. That is above the Healthcare sector average of 26.85. Scroll down for historical charts and peer comparison views.
The Healthcare sector average P/E ratio is about 26.85. Biogen is at 38.17, which is higher that average. That is roughly 42.2% above the sector mean. Use the comparison chart on this page to see how BIIB stacks up against individual peers as well.
Investors watch BIIB's P/E ratio because it compresses price and fundamentals into one number that is easy to compare across companies and over time. Biogen's latest reading is 38.17. Combining that with growth, ROE, and debt metrics usually beats relying on a single multiple.
Besides this p/e ratio page, Stockcircle has Biogen's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect P/E ratio (currently 38.17) with ownership activity and broader fundamentals.
The Healthcare average P/E ratio is about 26.85, while BIIB is at 38.17. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.
